Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.02 | -3.78 | -1.69 |
| FCF Yield | 1.54% | 0.72% | 0.49% | 1.72% |
| EV / EBITDA | 46.88 | 82.53 | 360.39 | 76.35 |
| Quality | ||||
| ROIC | 4.73% | 2.93% | 0.40% | 2.80% |
| Gross Margin | 98.24% | 98.36% | 98.39% | 98.52% |
| Cash Conversion Ratio | 1.09 | 0.95 | 8.20 | 2.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.57% | 14.48% | 14.71% | 16.52% |
| Free Cash Flow Growth | 139.44% | 65.43% | -77.00% | 56.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 1.15 | 8.10 | 1.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.20 | 0.16 | 0.16 |
| Cash Conversion Cycle | -242.86 | -301.93 | -416.83 | -440.34 |